CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 45 enrolled
Drug / intervention
ABNCoV2 Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04839146
NCT04839146Phase 1Completed
CompareCT.gov

First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naïve Adult Volunteers in Good Health

Radboud University Medical Center·interventional·Posted Apr 9, 2021·Updated Feb 17, 2026

In Brief

A Phase 1 clinical trial evaluating ABNCoV2 Vaccine for Covid19 and 2 related conditions. Completed, enrolled 45 participants across 1 site.

Detailed Summary

This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the immunogenicity-tolerability ratio 14 days following first vaccination with ABNCoV2.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection
CountriesNetherlands
CollaboratorsEuropean Union

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedApr 9, 2021
Enrollment StartMar 11, 2021
Primary CompletionDec 30, 2021
Study CompletionFeb 25, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.2 years ago

Interventions

ABNCoV2 Vaccinebiological

SARS-CoV-2 vaccine